Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.63 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 3/20 | 0.56 |
| ▸ | OGG1 | O15527 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7279604 | 0.95 | HTR1B (0.65) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL2925774 | 0.92 | HTR1B (0.62) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL29865967 | 0.87 | CNR2 (0.71) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL20911356 | 0.87 | CNR2 (0.71) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL29865545 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL4294120 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL8357769 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL29865585 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL20886144 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD | |
| SCHEMBL8780102 | 0.86 | CNR2 (0.69) | HTR1BKCNA3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885KCNA3 863/4885KDM4E 2142/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885KCNA3 863/4885KDM4E 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.